ClinicalTrials.gg
Active, not recruitingNCT05257980Updated Apr 14, 2026

Evaluation of Four New Ready to Drink Oral Nutritional Supplements: Adult ONS Trial

An interventional study of Dietary supplement (ONS) in Malnutrition, sponsored by Nutricia UK Ltd. Active, not recruiting at 19 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Nutricia UK Ltd (part of Danone) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Malnutrition by Danone — 2 open to participants now, 3 under way, none of them phase 3. Malnutrition · Danone.

Planned enrollment
3rd of 11
100 · median 73
Started
2021
the only one that year
No phase
9 of 12
1 open now
Registered
7th of 12
by date

Among the 12 studies in Malnutrition by Danone, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 9 with no phase, and was the 7th registered.

Malnutrition

1,278 studies on the registry are indexed under Malnutrition; 231 are open to participants now.

Browse Malnutrition studies →

Open to participants now

2 of the 12 studies in Malnutrition by Danone are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 150 Malnutrition studies recruiting now, 84 (56%) set no upper age limit and 44 (29%) stop at 75 or younger; 40 take children under 18; 30 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Malnutrition by Danone, or all of them as a file.
02

Study summary

The aim of this study is to evaluate compliance, acceptability, gastrointestinal tolerance, nutrient intake, appetite, nutritional status, and safety of four new ready to drink ONS. This is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period. During the intervention period, patients will receive one of the four ONS for 28 days alongside their routine diet.

Read the detailed description

Disease-related malnutrition (DRM) is a highly prevalent condition which leads to significant adverse health and economic burden. For the management of patients with DRM, oral nutritional supplements (ONS) are recommended and often prescribed (typically 1-3/day). ONS are energy- and nutrient-dense feeds that provide macro and micro-nutrients, designed to increase nutritional intake when diet alone is insufficient to meet daily nutritional requirements. The use of ONS has been shown to be effective for managing DRM by improving patient outcomes, including alleviating disease symptoms, aiding recovery from illness, regaining strength and improving quality of life, and reducing mortality. Additionally, the use of ONS has been reported to be cost effective in the healthcare setting due to reduced complications, fewer hospitalisations, and a reduced length of hospital stay.

An important outcome to enable ONS to be clinically and physiologically effective is compliance (i.e., how much the patient consumes relative to what is prescribed). Whilst good compliance to ONS in both hospital and community patients has been reported (78%), compliance in some patient groups has been reported to be as low as 35%. Poor compliance has been reported due to inability to consume the required volume, poor palatability, and taste fatigue. Furthermore, with increasing trends in plant-based food consumption and veganism, the lack of plant-based ONS may reduce compliance in vegan patients or those wishing to reduce animal-derived consumption for cultural or religious reasons. Consequently, there is a clear need for the development of different types of ONS which better cater both for patients with reported low compliance, but also patients with potentially higher compliance when presented with increased variety and choice.

The aim of this study is to evaluate compliance, acceptability, gastrointestinal tolerance, nutrient intake, appetite, nutritional status, and safety of four new ready to drink ONS. This is a prospective, longitudinal, 28-day intervention study with a 1-day baseline period. During the intervention period, patients will receive one of the four ONS for 28 days alongside their routine diet.

03

Conditions studied

  • Malnutrition

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • ≥16 years of age
  • Identified as being malnourished/at risk of malnutrition by malnutrition screening tools [i.e., MUST score ≥1, and/or using or requiring ONS at least once daily as part of nutritional management plan]
  • Expected to receive at least one bottle of ONS per day
  • Written or electronic from patient, or verbally given consent countersigned by a witness for those physically unable to sign

Exclusion criteria

Exclusion Criteria:

  • Patients receiving parenteral nutrition or ≥70% total energy requirements from enteral tube feeding
  • Patients with major hepatic dysfunction (i.e., decompensated liver disease)
  • Patients with major renal dysfunction [i.e., requiring filtration or stage 4/5 chronic kidney disease (CKD)]
  • Cancer patients likely to anticipate significant gastrointestinal disturbances/taste changes as a result of Systemic Anti-Cancer Therapy (SACT)
  • Patients with active/chronic gastrointestinal disease or impaired gastrointestinal function
  • Patients with significant dysphagia/high aspiration risk
  • Participation in other clinical intervention studies within 1 month of this study
  • Adults lacking mental capacity to consent
  • Allergy to any study product ingredients
  • Investigator concern regarding ability or willingness of patient to comply with the study requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dietary supplement (ONS)

    All patients will receive standardised dietary advice in addition to the ONS prescribed daily for 28 days. The ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The ONS prescribed will be the same throughout the 28 days and will be taken orally.

    Dietary Supplement: Dietary supplement (ONS)

Interventions

  • Dietary supplementDietary supplement (ONS)

    At baseline, the investigating dietitian/nurse will record several measures, including clinical history and symptoms over the previous 24 hours. In addition, patients who are already receiving an ONS will continue their prescribed ONS for 1 day in which their gastrointestinal tolerance, ONS compliance and acceptability will be recorded. All patients will then receive standardised dietary advice in addition to one of the four trial ONS products daily for 28 days. The type of ONS will be agreed with the patient and the investigating dietitian/nurse, and the ONS prescription will be determined on an individual basis by the investigating dietitian/nurse responsible for the patient's nutritional management (1-3 ONS per day; aligned with guidelines set out within the Malnutrition Pathway). The type of ONS prescribed will be the same throughout the 28 days and will be taken orally.

06

What researchers measure

Primary outcomes

  1. Compliance with ONS prescription

    Compliance with ONS prescription (% of bottle and how many bottles consumed) will be assessed daily by recording how much of the product was prescribed, compared to the amount consumed by the patient. The amount prescribed by the investigating dietitian/nurse will be recorded at the start of the study and any changes to this prescription will also be noted. For patients already receiving an ONS prior to enrolling onto the study, compliance will be assessed for 1 day at baseline. For all patients, compliance with the intervention ONS prescription will be assessed daily throughout the study and will be recorded by the patient/carer. For analysis, the mean daily % and the mean daily number of bottles consumed over the 28 days will be used.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

Secondary outcomes

  1. Nutrient Intake

    At baseline (Day 1), and after 1 week (Day 8), and end of the intervention period (Day 29), the investigating dietitian/nurse will conduct a 24-hour dietary recall with the patient to record all food, drink and nutritional feeds provided in the 24 hours prior. This information will be entered into a dietary analysis software (Nutritics, Dublin, Ireland) for assessment of nutritional intake (i.e., total energy and macro- and micronutrients).

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  2. Acceptability

    For patients already receiving an ONS prior to enrolling onto the study, acceptability of their currently prescribed ONS will be assessed for 1 day at baseline (Day 1). In all patients, acceptability of the prescribed intervention ONS will be assessed after 1 week (Day 8) and end of the intervention period (Day 29) using a questionnaire completed by the patient/carer. Questions will be rated on a 7-point Likert scale (Strongly Agree, Agree, Somewhat Agree, Neutral, Somewhat Disagree, Disagree, Strongly Disagree) and will relate to use, taste, aftertaste, thickness, and smell.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  3. Gastrointestinal Tolerance

    A standardised gastrointestinal (GI) tolerance questionnaire to capture perceived severity (none, mild, moderate or severe) of common gastrointestinal symptoms (diarrhoea, constipation, bloating, abdominal discomfort, vomiting and nausea) will be recorded at baseline (day 1) and at the end of each week (Days 8, 15, 22 and 29). Information about bowel movements will also be collected using the Bristol Stool Chart© at the same time points. The investigating dietitian/nurse will record usual GI symptoms at the baseline visit (Day 1; as reflective of the previous week) and if they are satisfied with the tolerance of the intervention feed at the end of the study (Day 29). The investigating dietitian/nurse will also assess any gastrointestinal tolerance goals for each patient.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  4. Anthropometry

    Historical weight will be recorded at baseline (Day 1), and current anthropometrics will be recorded upon screening, at baseline (Day 1) and at the end of the intervention period (Day 29) by the investigating dietitian/nurse. Body weight (kg) will be measured using standard methods to the nearest 0.1kg using a weighing scale without heavy clothing. Height will be measured at baseline only using standard measures to the nearest 0.1cm, without shoes or socks. Standardised methods to estimate height from segmental length (ulna length, knee height) will be used if standing height measurement is not possible. Height and weight measures will be used to calculate body mass index (BMI).

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  5. Nutritional Status

    The risk of DRM will be assessed during screening (as inclusion criteria), and at baseline (Day 1), and at the end of the intervention period (Day 29) using MUST (Appendix 1). MUST is a five-step screening tool to identify adults who are at risk of DRM.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  6. Dietetic Goal

    A dietetic goal (e.g., weight increase/maintenance) will be set by the investigating dietitian/nurse at baseline (Day 1) for each patient. At the end of the intervention period (Day 29), the investigating dietitian/nurse will assess and note if the dietetic goal was met.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  7. Appetite

    Subjective appetite profile will be measured by the patient prior to breakfast on Day 2 (prior to beginning the intervention), and after 1 week (Day 8) and at the end of the intervention period (Day 29) by means of visual analogue scales (VAS) from 0 (not at all) to 10 (extremely).

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  8. Appetite (SNAQ)

    Subjective appetite profile will be measured by the patient prior to breakfast on Day 2 (prior to beginning the intervention), and after 1 week (Day 8) and at the end of the intervention period (Day 29) by means of the Simplified Nutritional Appetite Questionnaire (SNAQ)

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  9. Medical and Dietetic History

    Medical history, including diagnoses and prescribed medications as well as relevant dietetic history (previous feeding regimens) will be recorded at baseline (Day 1) and any changes during the intervention will be noted by the investigating dietitian/nurse throughout the study.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

  10. Adverse Events

    Any adverse events will be recorded by the investigating dietitian/nurse.

    Time frame: Baseline (Day 1) - End of the study (Day 29)

07

Study locations

19 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Dec 2026, 63 months after the start.

Of 419 interventional studies with no phase under Malnutrition, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Feb 25, 2022
StartActual
Sep 27, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05257980
Lead sponsor
Nutricia UK Ltd
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Sep 27, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 14, 2026

Study contacts

Rebecca Stratton, PhD
study chair · Nutricia Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion